Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Eli Lilly stock is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Read the full earnings preview here.

GLP-1 drugs have become a focal point in the battle against obesity, a chronic condition affecting millions of Americans.

President Donald Trump has sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...